StemCyte Reports the US FDA’s Approval of Regenecyte Cord Blood Cell Therapy Product
Shots:
- The US FDA has granted approval to its BLA of Regenecyte, a cord blood stem cell therapy for transplantation to treat blood and immune disorders
- StemCyte is exploring its HPC, Cord Blood products for new areas such as chronic fatigue, aging-related diseases, and other conditions related to suboptimal health. P-II studies are underway for long COVID and acute stroke
- Regenecyte is an allogeneic stem cell therapy from umbilical cord blood, approved for unrelated donor hematopoietic progenitor cell transplants combined with an appropriate preparative regimen to restore hematopoietic and immune function in patients with hematopoietic disorders
Ref: StemCyte | Image: StemCyte
Related News:- Johnson & Johnson Submits sBLA to the US FDA for Subcutaneous Induction Regimen of Tremfya (Guselkumab) for Ulcerative Colitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
